Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi

S Luminari, E Viel, AJM Ferreri, F Zaja, E Chimienti, G Musuraca, Alessandra Tucci, M Balzarotti, Monica Tani, F Salvi, EA Pesce, A Ferrari, Anna Maria Liberati, A Spadea, D Marino, M Bruno-Ventre, Stefano Volpetti, Chiara Bottelli, E Ravaioli, F MerliM Spina

Research output: Contribution to journalArticle

Abstract

The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of "R-COMP" combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and October 2011, 50 evaluable patients were enrolled (median age, 76 years). Median baseline left ventricular ejection fraction (LVEF) was 60%. Ischemic cardiopathy was the most frequent preexisting cardiac disorder (35%), followed by atrial fibrillation (15%), left ventricular hypertrophy (13%), and baseline LVEF
Original languageEnglish
Pages (from-to)68-75
Number of pages8
JournalHematological Oncology
Volume36
Issue number1
DOIs
Publication statusPublished - 2018

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Stroke Volume
Comorbidity
Preexisting Condition Coverage
Left Ventricular Hypertrophy
Atrial Fibrillation
Multicenter Studies
Safety
liposomal doxorubicin

Cite this

Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. / Luminari, S; Viel, E; Ferreri, AJM; Zaja, F; Chimienti, E; Musuraca, G; Tucci, Alessandra; Balzarotti, M; Tani, Monica; Salvi, F; Pesce, EA; Ferrari, A; Liberati, Anna Maria; Spadea, A; Marino, D; Bruno-Ventre, M; Volpetti, Stefano; Bottelli, Chiara; Ravaioli, E; Merli, F; Spina, M.

In: Hematological Oncology, Vol. 36, No. 1, 2018, p. 68-75.

Research output: Contribution to journalArticle

Luminari, S, Viel, E, Ferreri, AJM, Zaja, F, Chimienti, E, Musuraca, G, Tucci, A, Balzarotti, M, Tani, M, Salvi, F, Pesce, EA, Ferrari, A, Liberati, AM, Spadea, A, Marino, D, Bruno-Ventre, M, Volpetti, S, Bottelli, C, Ravaioli, E, Merli, F & Spina, M 2018, 'Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi', Hematological Oncology, vol. 36, no. 1, pp. 68-75. https://doi.org/10.1002/hon.2425
Luminari, S ; Viel, E ; Ferreri, AJM ; Zaja, F ; Chimienti, E ; Musuraca, G ; Tucci, Alessandra ; Balzarotti, M ; Tani, Monica ; Salvi, F ; Pesce, EA ; Ferrari, A ; Liberati, Anna Maria ; Spadea, A ; Marino, D ; Bruno-Ventre, M ; Volpetti, Stefano ; Bottelli, Chiara ; Ravaioli, E ; Merli, F ; Spina, M. / Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. In: Hematological Oncology. 2018 ; Vol. 36, No. 1. pp. 68-75.
@article{f21663854e024075b70d413939712358,
title = "Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi",
abstract = "The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of {"}R-COMP{"} combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and October 2011, 50 evaluable patients were enrolled (median age, 76{\^A} years). Median baseline left ventricular ejection fraction (LVEF) was 60{\%}. Ischemic cardiopathy was the most frequent preexisting cardiac disorder (35{\%}), followed by atrial fibrillation (15{\%}), left ventricular hypertrophy (13{\%}), and baseline LVEF",
author = "S Luminari and E Viel and AJM Ferreri and F Zaja and E Chimienti and G Musuraca and Alessandra Tucci and M Balzarotti and Monica Tani and F Salvi and EA Pesce and A Ferrari and Liberati, {Anna Maria} and A Spadea and D Marino and M Bruno-Ventre and Stefano Volpetti and Chiara Bottelli and E Ravaioli and F Merli and M Spina",
year = "2018",
doi = "10.1002/hon.2425",
language = "English",
volume = "36",
pages = "68--75",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "1",

}

TY - JOUR

T1 - Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi

AU - Luminari, S

AU - Viel, E

AU - Ferreri, AJM

AU - Zaja, F

AU - Chimienti, E

AU - Musuraca, G

AU - Tucci, Alessandra

AU - Balzarotti, M

AU - Tani, Monica

AU - Salvi, F

AU - Pesce, EA

AU - Ferrari, A

AU - Liberati, Anna Maria

AU - Spadea, A

AU - Marino, D

AU - Bruno-Ventre, M

AU - Volpetti, Stefano

AU - Bottelli, Chiara

AU - Ravaioli, E

AU - Merli, F

AU - Spina, M

PY - 2018

Y1 - 2018

N2 - The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of "R-COMP" combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and October 2011, 50 evaluable patients were enrolled (median age, 76 years). Median baseline left ventricular ejection fraction (LVEF) was 60%. Ischemic cardiopathy was the most frequent preexisting cardiac disorder (35%), followed by atrial fibrillation (15%), left ventricular hypertrophy (13%), and baseline LVEF

AB - The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of "R-COMP" combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and October 2011, 50 evaluable patients were enrolled (median age, 76 years). Median baseline left ventricular ejection fraction (LVEF) was 60%. Ischemic cardiopathy was the most frequent preexisting cardiac disorder (35%), followed by atrial fibrillation (15%), left ventricular hypertrophy (13%), and baseline LVEF

U2 - 10.1002/hon.2425

DO - 10.1002/hon.2425

M3 - Article

VL - 36

SP - 68

EP - 75

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 1

ER -